1206896-20-9 Usage
Uses
Used in Pharmaceutical Industry:
2-t-Butyl-6-chlorobenzoxazole-7-(N-Methyl-N-Methoxy)sulfonaMide is used as a potential pharmaceutical compound for its unique structure and properties. Its benzoxazole ring and sulfonamide functional group may contribute to its biological activity, making it a candidate for the development of new drugs with specific therapeutic effects.
Used in Materials Science:
In the field of materials science, 2-t-Butyl-6-chlorobenzoxazole-7-(N-Methyl-N-Methoxy)sulfonaMide may be utilized for the development of novel materials with specific properties. Its complex structure and functional groups could be exploited to create materials with tailored characteristics, such as improved stability, reactivity, or selectivity.
Used in Organic Synthesis:
2-t-Butyl-6-chlorobenzoxazole-7-(N-Methyl-N-Methoxy)sulfonaMide can also be employed as a building block or intermediate in organic synthesis. Its unique structure and functional groups may enable the synthesis of new compounds with diverse applications, such as pharmaceuticals, agrochemicals, or specialty chemicals.
Further research and analysis of 2-t-Butyl-6-chlorobenzoxazole-7-(N-Methyl-N-Methoxy)sulfonaMide are necessary to fully understand its potential uses and effects, as well as to optimize its synthesis and application in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1206896-20-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,6,8,9 and 6 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1206896-20:
(9*1)+(8*2)+(7*0)+(6*6)+(5*8)+(4*9)+(3*6)+(2*2)+(1*0)=159
159 % 10 = 9
So 1206896-20-9 is a valid CAS Registry Number.
1206896-20-9Relevant articles and documents
ORGANIC COMPOUNDS
-
Page/Page column 35, (2010/03/02)
The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.